Table 1.
Ocular drug delivery systems in clinical trials or in development.
| Delivery platform | Drug | Method of delivery | Developmental stage |
|---|---|---|---|
| Clearside Biomedical microneedle | Triamcinolone acetonide | Suprachoroidal injection |
P2(TYBEE) P3(PEACHTREE) |
| Microcannulation | Stem cell (CNTO 2476) | Suprachoroidal injection | P1/2 |
| Microcannulation | Iluvien® | Suprachoroidal injection | Ex-US P1 |
| Encapsulated cell technology | Ciliary neurotrophic factor (CNTF) | Intravitreal implant | P2 |
| Retiset® | Fluocinolone acetonide | Intravitreal implant | Launched |
| Iluvien® | Fluocinolone acetonide | Intravitreal implant | Launched |
| Ozurdex® | Dexamethasone | Intravitreal implant | Launched |
| PLGA nanoparticles | Bevacizumab | Intravitreal implant | Pre-clinical |
| PLGA microparticles | Bevacizumab | Intravitreal implant | Pre-clinical |
| Graybug vision GB-102 | Sunitinib malate | Intravitreal implant | P1/2a |
| Ocular therapeutix OTX-IVT | Aflibercept | Intravitreal implant | Pre-clinical |
| Ocular therapeutix OTX-TKI | Tyrosine kinase inhibitor | Intravitreal implant | Ex-US P1 |
| Thermoresponsive hydrogel | Bevacizumab or ranibizumab | Intravitreal implant | Pre-clinical |
| In situ hydrogel | Bevacizumab | Intravitreal implant | Pre-clinical |
| Microsphere-thermoresponsive composite system | Bevacizumab, ranibizumab, or aflibercept | Intravitreal implant | Pre-clinical |
| Port delivery system | Ranibizumab | Intravitreal implant | P2 |